'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.

Hyrimoz®, (GP2017 [SDZ-ADL]), is a biosimilar to Humira® (REF-ADL). SDZ-ADL was approved in 2018 by both the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) for the indications of REF-ADL not protected by orphan exclusivity. In 2023, the US FDA and EMA also approved a citrate-free high-concentration formulation (HCF) of SDZ-ADL. Approval of SDZ-ADL was based on data gathered using the US FDA, EMA and World Health Organization (WHO)-recommended step-wise Totality of Evidence approach. This approach is a robust dataset confirming high confidence in analytical, functional, pharmacokinetic (PK) and clinical biosimilarity between the biosimilar and reference medicine determined through analytical and clinical investigation. Evidence supporting the biosimilarity of SDZ-ADL and REF-ADL was reported at each stage of investigation. Comprehensive comparative analytical and functional assessments demonstrated that SDZ-ADL was analytically indistinguishable from REF-ADL in required critical quality attributes, including receptor binding. Phase I clinical data showed PK similarity of SDZ-ADL and REF-ADL in healthy volunteers, with similar safety, tolerability and immunogenicity profiles. Phase III confirmatory efficacy and safety studies, ADACCESS (included in US/EU dossiers) and ADMYRA (separate to US/EU dossiers), both confirmed that SDZ-ADL's efficacy, safety, and immunogenicity matched REF-ADL in all patient groups with no clinically meaningful differences. More recently, this data package was the basis for a citrate-free HCF of SDZ-ADL to be developed, and its PK, safety and immunogenicity were confirmed against the initially approved formulation of SDZ-ADL. Overall, the Totality of Evidence provided for biosimilar adalimumab, SDZ-ADL, confirmed the analytical, functional and clinical similarity of SDZ-ADL to REF-ADL, supporting its regulatory approval and providing a data bridge with which to evaluate and support the approval of citrate-free HCF SDZ-ADL for clinical use.

Gaylis N ，Both C ，Lemke L ，von Richter O ，Yamauchi P ... -  《-》

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

Blauvelt A ，Leonardi CL ，Gaylis N ，Jauch-Lembach J ，Balfour A ，Lemke L ，Hachaichi S ，Brueckmann I ，Festini T ，Wiland P ... -  《-》

A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body.

Danese S ，Wiland P ，Cohen R ，Gaylis N ，Both C ，Jathanakodi S ，Fey C ，Lemke L ，Blauvelt A ... -  《-》

The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.

McClellan JE ，Ómarsdóttir S ，Roy N ，Berger V ，Michel C ，Berti F ... -  《-》

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.

Wiland P ，Jeka S ，Dokoupilová E ，Brandt-Jürgens J ，Miranda Limón JM ，Cantalejo Moreira M ，Cabello RV ，Jauch-Lembach J ，Thakur A ，Haliduola H ，Brueckmann I ，Gaylis NB ... -  《-》